MA28075A1 - Dérivés d'imino-acides bicycliques utilisés comme inhibiteurs de métalloprotéinases de matrice - Google Patents
Dérivés d'imino-acides bicycliques utilisés comme inhibiteurs de métalloprotéinases de matriceInfo
- Publication number
- MA28075A1 MA28075A1 MA28892A MA28892A MA28075A1 MA 28075 A1 MA28075 A1 MA 28075A1 MA 28892 A MA28892 A MA 28892A MA 28892 A MA28892 A MA 28892A MA 28075 A1 MA28075 A1 MA 28075A1
- Authority
- MA
- Morocco
- Prior art keywords
- diseases
- matrix metalloproteinases
- chronic
- inhibitors
- acid derivatives
- Prior art date
Links
- 102000002274 Matrix Metalloproteinases Human genes 0.000 title abstract 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000017667 Chronic Disease Diseases 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 201000008482 osteoarthritis Diseases 0.000 abstract 2
- 208000030090 Acute Disease Diseases 0.000 abstract 1
- 208000036487 Arthropathies Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000018083 Bone metabolism disease Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 206010058112 Chondrolysis Diseases 0.000 abstract 1
- 208000027932 Collagen disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000012659 Joint disease Diseases 0.000 abstract 1
- 208000019428 Ligament disease Diseases 0.000 abstract 1
- 206010065433 Ligament rupture Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000000112 Myalgia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000031481 Pathologic Constriction Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000002808 connective tissue Anatomy 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000005499 meniscus Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 210000004417 patella Anatomy 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 208000005801 spondylosis Diseases 0.000 abstract 1
- 230000036262 stenosis Effects 0.000 abstract 1
- 208000037804 stenosis Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 230000036269 ulceration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des composés de formule (I) appropriés pour la production de médicaments servant à la prophylaxie et à la thérapie de maladies dont l'évolution est liée à une activité accrue des métalloprotéinases matricielles. Parmi ces maladies, citons: les maladies articulaires dégénératives telles que les ostéoarthroses, les spondyloses, la chondrolyse consécutive à un traumatisme articulaire ou à une immobilisation articulaire prolongée après une lésion du ménisque ou de la rotule ou des ruptures de ligaments, ou bien les maladies du tissu conjonctif telles que les collagénoses, les parodontolyses, les troubles de la cicatrisation, ou les maladies chroniques de l'appareil moteur telles que les arthrites infectieuses, chroniques ou aiguës de nature mimunologique ou liées au métabolisme, les arthropathies, les myalgies ou les troubles du métabolisme osseux, ou une ulcération, une athérosclérose ou une sténose, ou bien une maladie inflammatoire ou une maladie cancéreuse, la formation de métastases tumorales, la cachexie, l'anorexie ou un choc septique.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10344936A DE10344936A1 (de) | 2003-09-27 | 2003-09-27 | Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28075A1 true MA28075A1 (fr) | 2006-08-01 |
Family
ID=34353126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28892A MA28075A1 (fr) | 2003-09-27 | 2006-03-27 | Dérivés d'imino-acides bicycliques utilisés comme inhibiteurs de métalloprotéinases de matrice |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1670766B1 (fr) |
| JP (1) | JP4861179B2 (fr) |
| KR (1) | KR20060086367A (fr) |
| CN (1) | CN1856478B (fr) |
| AR (1) | AR046165A1 (fr) |
| AT (1) | ATE550327T1 (fr) |
| AU (1) | AU2004275937A1 (fr) |
| BR (1) | BRPI0414594A (fr) |
| CA (1) | CA2539731A1 (fr) |
| DE (1) | DE10344936A1 (fr) |
| IL (1) | IL174040A0 (fr) |
| MA (1) | MA28075A1 (fr) |
| ME (1) | MEP33008A (fr) |
| MX (1) | MXPA06002927A (fr) |
| MY (1) | MY139830A (fr) |
| NO (1) | NO20061837L (fr) |
| NZ (1) | NZ546158A (fr) |
| PE (1) | PE20050432A1 (fr) |
| RS (1) | RS20060194A (fr) |
| RU (1) | RU2335494C2 (fr) |
| TW (1) | TW200520755A (fr) |
| UY (1) | UY28539A1 (fr) |
| WO (1) | WO2005030728A1 (fr) |
| ZA (1) | ZA200601501B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004031850A1 (de) * | 2004-06-30 | 2006-01-26 | Sanofi-Aventis Deutschland Gmbh | Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| DE102004031620A1 (de) * | 2004-06-30 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln |
| DE102005002500A1 (de) | 2005-01-19 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen |
| DE102005015040A1 (de) * | 2005-03-31 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| US8790714B2 (en) | 2007-08-03 | 2014-07-29 | Nucitec, S.A. De C.V. | Compositions and methods for treatment and prevention of osteoarthritis |
| WO2025224168A1 (fr) | 2024-04-24 | 2025-10-30 | Idorsia Pharmaceuticals Ltd | Dérivés d'arylsulfone et de sulfanone utilisés en tant que modulateurs du récepteur de l'orexine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201303B (fr) * | 1990-07-05 | 1993-03-01 | Hoffmann La Roche | |
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| FR2701480B1 (fr) * | 1993-02-15 | 1995-05-24 | Sanofi Elf | Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
| US6207672B1 (en) * | 1995-11-13 | 2001-03-27 | Aventis Pharma Deutschland Gmbh | Cyclic and heterocyclic N-substituted α-iminohydroxamic and carboxyclic acids |
| KR100339296B1 (ko) * | 1996-08-28 | 2002-06-03 | 데이비드 엠 모이어 | 헤테로고리성 메탈로프로테아제 억제제 |
| PL334846A1 (en) * | 1997-01-23 | 2000-03-27 | Hoffmann La Roche | Sulphamidic inhibitors of metaloproteases |
| DE19719817A1 (de) * | 1997-05-13 | 1998-11-19 | Hoechst Ag | Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren |
| DE10300015A1 (de) * | 2003-01-03 | 2004-07-15 | Aventis Pharma Deutschland Gmbh | Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen |
| DE102004031620A1 (de) * | 2004-06-30 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln |
-
2003
- 2003-09-27 DE DE10344936A patent/DE10344936A1/de not_active Withdrawn
-
2004
- 2004-09-14 CA CA002539731A patent/CA2539731A1/fr not_active Abandoned
- 2004-09-14 WO PCT/EP2004/010248 patent/WO2005030728A1/fr not_active Ceased
- 2004-09-14 NZ NZ546158A patent/NZ546158A/en unknown
- 2004-09-14 ME MEP-330/08A patent/MEP33008A/xx unknown
- 2004-09-14 RS YUP-2006/0194A patent/RS20060194A/sr unknown
- 2004-09-14 KR KR1020067005981A patent/KR20060086367A/ko not_active Ceased
- 2004-09-14 AU AU2004275937A patent/AU2004275937A1/en not_active Abandoned
- 2004-09-14 CN CN2004800279029A patent/CN1856478B/zh not_active Expired - Fee Related
- 2004-09-14 JP JP2006527308A patent/JP4861179B2/ja not_active Expired - Fee Related
- 2004-09-14 BR BRPI0414594-1A patent/BRPI0414594A/pt not_active IP Right Cessation
- 2004-09-14 AT AT04786944T patent/ATE550327T1/de active
- 2004-09-14 EP EP04786944A patent/EP1670766B1/fr not_active Expired - Lifetime
- 2004-09-14 RU RU2006114352/04A patent/RU2335494C2/ru not_active IP Right Cessation
- 2004-09-14 MX MXPA06002927A patent/MXPA06002927A/es active IP Right Grant
- 2004-09-21 PE PE2004000918A patent/PE20050432A1/es not_active Application Discontinuation
- 2004-09-23 TW TW093128791A patent/TW200520755A/zh unknown
- 2004-09-23 AR ARP040103437A patent/AR046165A1/es not_active Application Discontinuation
- 2004-09-25 MY MYPI20043935A patent/MY139830A/en unknown
- 2004-09-27 UY UY28539A patent/UY28539A1/es unknown
-
2006
- 2006-02-21 ZA ZA200601501A patent/ZA200601501B/en unknown
- 2006-03-01 IL IL174040A patent/IL174040A0/en unknown
- 2006-03-27 MA MA28892A patent/MA28075A1/fr unknown
- 2006-04-26 NO NO20061837A patent/NO20061837L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MY139830A (en) | 2009-10-30 |
| TW200520755A (en) | 2005-07-01 |
| AR046165A1 (es) | 2005-11-30 |
| UY28539A1 (es) | 2005-04-29 |
| EP1670766B1 (fr) | 2012-03-21 |
| NO20061837L (no) | 2006-06-01 |
| RU2006114352A (ru) | 2006-08-27 |
| KR20060086367A (ko) | 2006-07-31 |
| NZ546158A (en) | 2008-11-28 |
| BRPI0414594A (pt) | 2006-11-07 |
| RU2335494C2 (ru) | 2008-10-10 |
| WO2005030728A1 (fr) | 2005-04-07 |
| CA2539731A1 (fr) | 2005-04-07 |
| JP4861179B2 (ja) | 2012-01-25 |
| DE10344936A1 (de) | 2005-04-21 |
| RS20060194A (sr) | 2008-08-07 |
| ZA200601501B (en) | 2007-04-25 |
| PE20050432A1 (es) | 2005-07-21 |
| JP2007506690A (ja) | 2007-03-22 |
| EP1670766A1 (fr) | 2006-06-21 |
| ATE550327T1 (de) | 2012-04-15 |
| MEP33008A (en) | 2010-10-10 |
| IL174040A0 (en) | 2006-08-01 |
| MXPA06002927A (es) | 2006-06-14 |
| CN1856478A (zh) | 2006-11-01 |
| AU2004275937A1 (en) | 2005-04-07 |
| CN1856478B (zh) | 2010-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69712496T2 (de) | Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren | |
| JP2871849B2 (ja) | 化合物 | |
| MA29429B1 (fr) | Composes d'arylamine substitues et leur utilisation comme modulateurs de 5-ht6 | |
| TNSN99106A1 (fr) | Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
| TNSN96107A1 (fr) | Benzylaminopiperidines substitues et compositions pharmaceutiques les contenant | |
| EP1619192A3 (fr) | Composes azapolycycliques a fusion aryle | |
| JP2002508352A (ja) | ４（３）置換−４（３）−アミノメチル−（チオ）ピラン又はピペリジン誘導体（＝ガバペンチン類似体）、それらの製法および神経病理学的疾患の治療における使用 | |
| SK61697A3 (en) | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents | |
| MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
| MA26696A1 (fr) | Derives de tetrahydrobenzazepine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TW200502221A (en) | Novel lactams and uses thereof | |
| BR0111140A (pt) | Forma polimórfica, composição farmacêutica, métodos para o tratamento de uma doença inflamatória, de uma doença mediada por ciclooxigenase, de dor, e, processo para fabricar um polimorfo de forma v | |
| MA28075A1 (fr) | Dérivés d'imino-acides bicycliques utilisés comme inhibiteurs de métalloprotéinases de matrice | |
| US20060084695A1 (en) | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | |
| TNSN02036A1 (fr) | Derives d'acide 3- heterocyclylpropano-hydroxamique nouveaux, et compositions les contenant. | |
| DE60106117D1 (de) | 2-oxo-Imidazolidin-4-Carboxsäure Hydroxamid Derivate als Matrix Metalloproteinase Inhibitoren | |
| EA009767B1 (ru) | Производные пролина, обладающие сродством к альфа-2-дельта субъединице кальциевого канала | |
| JP2005513049A5 (fr) | ||
| WO2005097762A3 (fr) | 1,3,4-oxadiazol-2-ones utilises en tant que modulateurs de ppar delta et utilisation associee | |
| WO2009048586A1 (fr) | Composés d'imidazoline substitués | |
| WO2003104255A3 (fr) | Derives de 2-cyclohexyl-4-phenyl-1h-imidazoles substitues | |
| JP3576193B2 (ja) | ビフェニルメチル置換バレリルアミド誘導体 | |
| EA000438B1 (ru) | Производные эпоксиянтарной кислоты | |
| KR100306520B1 (ko) | 아릴리덴-1-아자사이클로알칸과아릴알킬-1-아자사이클로알칸,이들의염및이들화합물을함유하는약제 |